Q-omics provides the consensus-scored KRT14 profile across patient tissues and cancer cell-line models. KRT14 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KRT14 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, KRT14 protein abundance shows 16,021 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, KICH, and HNSC as cancer lineages where KRT14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT14 survival associations across molecular data types. KRT14 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT14 RNA expression–survival associations across cancer types. High KRT14 expression shows unfavorable associations in MESO, KIRC, KIRP and COAD, but favorable associations in BRCA and THYM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for KRT14 RNA expression.
This table summarizes KRT14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KRT14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT14 shows lower tumor expression in KICH and BRCA and higher tumor expression in LUSC, HNSC, BLCA and THCA. The KICH box plot shows higher KRT14 RNA expression in normal versus tumor tissue (log2 FC = −0.130, t-test p < 0.001).
This table shows molecular features associated with KRT14 in patient tissues and cancer cell lines. In patient samples, KRT14 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
